ARTICLE | Strategy
Cephalon Blasts into CV
Cephalon enters cardiovascular space with Mesoblast stem cell deal
December 13, 2010 8:00 AM UTC
Cephalon Inc. continued its expansion into specialty disease areas last week via a partnership with Mesoblast Ltd. that marks Cephalon's first foray into the cardiovascular space.
Cephalon received worldwide rights to Mesoblast's adult Mesenchymal Precursor Stem Cell (MPC) technology in three treatment areas: neurodegenerative disease; augmenting hematopoietic stem cell transplantation in cancer patients; and cardiovascular disease...